Group 1 - Biotech stocks have shown significant recovery and are now among the top performers in the market over the past few quarters [1] - The iShares Biotechnology ETF (IBB) experienced a substantial decline from Q4 2024 to April 2025, underperforming compared to the S&P [1]

Market Overview - U.S. stock futures declined on Monday following a mixed close on Friday, with major benchmark indices showing lower futures [1] - Investors are focused on upcoming earnings reports from companies such as UnitedHealth Group, General Motors, Microsoft, Meta Platforms, Tesla, and Starbucks [1] - The Federal Open Market Committee's interest rate decision is anticipated on Wednesday [1] Treasury Yields - The yield on the 10-year Treasury bond is at 4.21%, while the two-year bond yield stands at 3.59% [2] - Market projections indicate a 97.2% likelihood that the Federal Reserve will keep interest rates unchanged in January [2] Index Performance - Dow Jones decreased by 0.12%, S&P 500 fell by 0.24%, Nasdaq 100 dropped by 0.44%, and Russell 2000 declined by 0.29% [3] - SPDR S&P 500 ETF Trust (SPY) was down 0.22% at $687.69, and Invesco QQQ Trust ETF (QQQ) declined 0.43% to $620.04 in premarket trading [3] Stocks in Focus - Baker Hughes Co. reported a 3.74% increase in premarket trading after posting adjusted earnings of 78 cents per share, exceeding estimates of 67 cents [7] - Sarepta Therapeutics Inc. saw a 6.72% rise after completing a trial commitment for its PMO therapies and releasing third-quarter results [7] - Nucor Corp. is projected to report quarterly earnings of $1.91 per share on revenue of $7.87 billion [7] - WR Berkley Corp. is expected to report earnings of $1.13 per share on revenue of $3.66 billion, with a weaker price trend according to Benzinga's Edge Stock Rankings [15] Analyst Insights - Mohamed El-Erian notes a "2025 Paradox" where financial markets remain resilient despite geopolitical tensions, with U.S. economic activity appearing robust [11] - El-Erian anticipates the Federal Reserve will maintain interest rates, with a focus on corporate earnings from tech giants and political issues affecting market stability [12][13] Upcoming Economic Data - Key economic reports to watch include durable-goods orders, consumer confidence data, and the Federal Reserve's interest rate decision [17]

Core Insights - The recent update from Greenwich LifeSciences, Inc. (GLSI) focuses on manufacturing validation and regulatory progress rather than solely on clinical results [1] Company Overview - Greenwich LifeSciences has received FDA approval, indicating progress in its regulatory journey [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The analyst has been active in the investment space for five years, with a focus on identifying promising biotechnology companies [1] Investment Focus - The analyst emphasizes evaluating the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector [1]

Group 1 - The article discusses the resurgence of SPACs (Special Purpose Acquisition Companies) in 2025 after a decline in popularity due to disappointing returns and increased federal oversight [4][5] - New SPAC issuances more than doubled from 2024 to 2025, indicating a positive trend in the market, driven by experienced SPAC sponsors returning [5] - Cormorant Asset Management has launched Helix Acquisition Corp. III, raising $150 million through an IPO, with plans to focus on healthcare or healthcare-related industries [8] Group 2 - Helix Acquisition Corp. III sold 15 million shares at $10 each, exceeding its initial projection by 2.5 million shares, and began trading on Nasdaq under the ticker "HLXC" [8] - Cormorant Asset Management manages over $2.4 billion and has previously taken three SPACs public since 2022, successfully finding merger partners for its earlier SPACs [8] - The current market environment presents unique opportunities for SPACs, as many drug startups have remained private longer, creating a backlog of mature companies ready for public markets [7][8]

Core Viewpoint - Legend Biotech Corporation (NASDAQ:LEGN) is viewed positively by analysts, with Deutsche Bank and Cantor Fitzgerald both maintaining bullish ratings and setting price targets of $60 and $74 respectively, driven by expectations of strong clinical trial results and significant sales growth in its oncology pipeline [1][4]. Group 1: Analyst Ratings and Price Targets - Deutsche Bank reiterated a Buy rating on Legend Biotech and set a price target of $60, anticipating topline results from its first in-vivo CAR T program by year-end [1]. - Cantor Fitzgerald reaffirmed an Overweight rating with a price target of $74, highlighting the expected 100% year-over-year sales increase of Carvykti to $2 billion [4]. Group 2: Clinical Development and Pipeline - Initial preclinical data indicate robust dose-dependent CAR-T expansion in non-human primates, with sustained peripheral B-cell elimination observed from day 8 to day 36, suggesting in vivo CAR-T cells have properties akin to traditional CAR-T treatments [2]. - Legend Biotech aims to achieve profitability by 2026 while continuing to develop its pipeline, focusing on in vivo and allogeneic CAR-T therapies [3]. Group 3: Company Overview - Legend Biotech is a global clinical-stage biotechnology company dedicated to discovering, developing, and commercializing novel cell therapies, primarily targeting cancer and severe diseases, leveraging technologies like CAR-T cell therapy [5].

Core Insights - The article discusses the 15 best S&P 500 dividend stocks to consider for investment in 2026, emphasizing the stability that dividend stocks can provide during market downturns [1] Dividend and Buyback Strategy - Dan Lefkovitz from Morningstar Indexes suggests that combining dividend-paying stocks with companies that actively buy back shares can yield better returns compared to a high-dividend-only strategy [2] - An index that includes both dividends and buybacks has outperformed a high-dividend-only index over the past three years, although it still lags behind the overall US market [2] Cash Return to Shareholders - The article highlights the difference in how companies return cash to shareholders, noting that dividends are a long-term commitment while buybacks are more flexible and often increase when management perceives the stock as undervalued [3] - Large technology companies have been leading in buyback activities, while dividend payments are primarily concentrated in sectors like financials, utilities, energy, and consumer staples [3] International Dividend Yields - Income-focused investors are encouraged to look beyond the US, as domestic dividend yields have decreased to approximately 1.1%, while some European regions offer yields above 3% [4] - Caution is advised against chasing high yields, as unusually high payouts may indicate underlying business stress and potential future dividend cuts [4] Methodology for Stock Selection - The selection process for the 15 best dividend stocks involved screening S&P 500 companies with a market cap of at least $10 billion, focusing on those with stable dividends and yields around 2% as of January 21 [6] - The final list was based on popularity among hedge funds, utilizing data from Insider Monkey's Q3 2025 database [6][7] Company-Specific Insights - **Verizon Communications Inc. (NYSE:VZ)**: - Holds a dividend yield of 7.06% as of January 21, with 60 hedge fund holders [8] - Bernstein has cut its price target for Verizon to $44, citing increased competition in the telecom industry [8] - Verizon's $20 billion acquisition of Frontier Communications was approved, with commitments to expand fiber internet and wireless coverage in California [9] - **Amgen Inc. (NASDAQ:AMGN)**: - Has a dividend yield of 3.05% as of January 21, with 62 hedge fund holders [11] - Bernstein downgraded Amgen to Market Perform, indicating 2026 may be a waiting year for its product MariTide [11] - Amgen announced the acquisition of Dark Blue Therapeutics for up to $840 million, enhancing its oncology pipeline [12][13]

Merck is no longer in talks to acquire biotech firm Revolution Medicines after the two companies couldn’t agree on a price, the Wall Street Journal reported, citing people familiar with the matter. https://t.co/OzqpyBp2tV ...

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion. https://t.co/CT338S45B4 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. ACROBIOSYSTEMS CO., LTD 北京百普賽斯生物科技股份有限公司 (the "Company") (A joint stock company incorporated in the People's Republic of China with limited liabil ...

Core Insights - The article highlights the top-performing analysts in the U.S. for the year 2025, as ranked by TipRanks based on their success rates and average returns [1][2]. Analyst Rankings - **Sam Slutsky – LifeSci Capital**: Achieved the highest ranking with a success rate of 67.74% and an average return of 62.4%. His notable recommendation on Abivax SA (ABVX) yielded a return of 894.81% [3]. - **Richard Shannon – Craig-Hallum**: Ranked second with a success rate of 61.87% and an average return of 36.9%. His top call on Aeva Technologies (AEVA) generated a return of 822.14% [4]. - **Joseph Stringer – Needham**: Secured the third position with a success rate of 79.17% and an average return of 38.2%. His best recommendation was for Inozyme Pharma (INZY), which returned 361.9% [5]. - **Myles Minter – William Blair**: Fourth place with a success rate of 66.93% and an average return of 28.8%. His top recommendation on Ovid Therapeutics (OVID) yielded a profit of 350% [6]. - **Ruben Roy – Stifel Nicolaus**: Fifth on the list with a success rate of 75.68% and an average return of 35.3%. His best call on CoreWeave (CRWV) generated a return of 293.2% [7]. - **Seamus Fernandez – Guggenheim**: Ranked sixth with a success rate of 78.57% and an average return of 40.6%. His best recommendation was for Cidara Therapeutics (CDTX), which returned 244.7% [8]. - **Thomas Smith – Leerink Partners**: Seventh place with an average return of 30.7% and a success rate of 65.22%. His best recommendation on Abivax yielded a return of 880.34% [9]. - **Mark Miller – Benchmark Co.**: Eighth with a success rate of 59.8% and an average return of 11.1%. His top call on SanDisk (SNDK) generated a return of 470.6% [11]. - **Allison Bratzel – Piper Sandler**: Ninth position with a success rate of 63.64% and an average return of 58.2%. His recommendation for Abivax also yielded a return of 894.81% [12]. - **Julian Harrison – BTIG**: Tenth with a success rate of 59.38% and an average return of 37%. His top recommendation on Abivax generated a return of 1,057.12% [13].